Background/Objective: Although often called a “silent disease”, HBV entails a significant disease and financial burden for the health system. An attempt to provide detailed estimates of the direct cost of this – rather neglected – disease in Greece comprised the objective of this study. Methods: The medical records of 254 patients diagnosed with HBV and monitored in the Hepatology Unit of the ‘Attikon’ university hospital provided the basis for the analysis. Detailed resource use data (physician visits, medications, labwork, and hospitalizations) were derived from the patients’ records for a retrospective 12month period, before their most recent visit to the clinic. Calculations followed a third-party payer perspective, according to official prices and tariffs, and are expressed in year 2015 Euros.
Comments: 3 Pages.
[v1] 2017-09-23 04:51:52
Unique-IP document downloads: 4 times
Vixra.org is a pre-print repository rather than a journal. Articles hosted may not yet have been verified by peer-review and should be treated as preliminary. In particular, anything that appears to include financial or legal advice or proposed medical treatments should be treated with due caution. Vixra.org will not be responsible for any consequences of actions that result from any form of use of any documents on this website.
Add your own feedback and questions here:
You are equally welcome to be positive or negative about any paper but please be polite. If you are being critical you must mention at least one specific error, otherwise your comment will be deleted as unhelpful.